🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Andrea Wang‐Gillam

Cubist Pharmaceuticals (United States)

ORCID: 0000-0003-0458-7614
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
3.4Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Nature Communications(2021)10.1038/s41467-021-25177-3
Top 8%
2.7DataRank
Top 8%109 citations

Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl +94 more

Papers

Driven by 14 papers — median percentile 81. Top paper: “Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment”.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Nature Communications(2021)10.1038/s41467-021-25177-3
Top 8%
2.7DataRank
Top 8%109 citations

Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl +94 more

Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers

Journal of Clinical Investigation(2021)10.1172/jci152670
N/A
2.1DataRank · unranked
86 citations

Leslie Cope, Amanda N. Ruggieri, Robert A. Anders, Anne M. Noonan, Laura W. Goff +24 more

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

NAR Cancer(2022)10.1093/narcan/zcac014
Top 31%
0.652DataRank
Top 31%22 citations

Michael W. Lloyd, Jeffrey W. Grover, Nan Xiao, Sara Seepo, Sai Lakshmi Subramanian +95 more

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

Nature Communications(2024)10.1038/s41467-024-46811-w
N/A
0.524DataRank · unranked
32 citations

Peng Liu, Kuljeet Seehra, Sapana Bansod, Yali Chen, Kiran Zahra +22 more

Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0535
N/A
0.512DataRank · unranked
12 citations

Devora Delman, Jiayi Yu, Mingen Liu, Joey H. Li, Liti Zhang +8 more

MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial

International Journal of Radiation Oncology*Biology*Physics(2022)10.1016/j.ijrobp.2022.07.015
N/A
0.406DataRank · unranked
14 citations

Jeffrey R. Olsen, Olga L. Green, R Chin, William G. Hawkins, Ryan C. Fields +16 more

Neoantigen DNA vaccines are safe, feasible, and capable of inducing neoantigen-specific immune responses in patients with triple negative breast cancer

medRxiv(2021)10.1101/2021.11.19.21266466
N/A
0.396DataRank · unranked
13 citations

S. Peter Goedegebuure, Nancy B. Myers, Tammi L. Vickery, Michael D. McLellan, Feng Gao +23 more

Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma

Gastroenterology(2024)10.1053/j.gastro.2024.01.013
N/A
0DataRank · unranked
18 citations

Sarah Colby, Ignacio Garrido‐Laguna, Yuqing Xue, Renee B. Chang, Devora Delman +14 more

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4504
N/A
0DataRank · unranked
115 citations

Mai T. Duong, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam +7 more

Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.419
N/A
0DataRank · unranked
2 citations

Mai T. Duong, Renee B. Chang, Yuqing Xue, Devora Delman, Ignacio Garrido‐Laguna +15 more

Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4131
N/A
0DataRank · unranked
0 citations

Mai T. Duong, Robert D. Boutin, Leon Lenchik, Jiyoon Kim, Namita Gandhi +11 more

Phase I dose escalation and expansion study of defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment-refractory pancreatic cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4146
N/A
0DataRank · unranked
1 citations

Kian-Huat Lim, Robert R. McWilliams, Rama Suresh, A. Craig Lockhart, Amberly Brown +15 more

Data from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma

(2023)10.1158/1078-0432.c.6525797
N/A
0DataRank · unranked
0 citations

Lin Li, Hongmei Jiang, Brett L. Knolhoff, A. Craig Lockhart, Andrea Wang‐Gillam +4 more

TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations

Journal of Clinical Investigation(2020)10.1172/jci137660
N/A
0DataRank · unranked
33 citations

Namrata Khurana, Daoxiang Zhang, Yi Cheng, Lin Li, Qing Wei +6 more